Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death
Menée à partir de données portant sur 462 patients atteints d'un cancer de la prostate avec score de Gleason égal à 8 et traités par curiethérapie et radiothérapie externe en combinaison ou non avec un traitement anti-androgénique (durée médiane de suivi : 7,6 ans), cette étude évalue la mortalité spécifique et la mortalité toutes causes confondues en fonction des deux grades qui composent le score de Gleason (3 + 5, 5 + 3 ou 4 + 4)
The International Society of Urological Pathology recommends that Gleason score (GS) 8 prostate cancer (PC) is one prognostic category, yet heterogeneity in cancer control potentially exists amongst men with GS 3 + 5/5 + 3 versus GS 4 + 4 PC. We compared PC-specific mortality (PCSM) and all-cause mortality (ACM) risk among men with GS 3 + 5/5 + 3 versus GS 4 + 4 PC using competing-risks and Cox regression analyses, adjusting for age, known PC prognostic factors, treatment, and a treatment propensity score. Between 1998 and 2012, 462 men with GS 8 PC were treated using brachytherapy with supplemental external-beam radiation therapy and/or androgen deprivation therapy at the Chicago Prostate Cancer Center. After a median follow-up of 7.6 yr, 118 men died, 26 of PC. PCSM (adjusted hazard ratio [AHR] 2.77, 95% confidence interval [CI] 1.13–6.80; p = 0.026) and ACM (AHR 1.75, 95% CI 1.06–2.87; p = 0.028) were significantly higher for men with GS 3 + 5/5 + 3 PC than for men with GS 4 + 4 PC. Subcategorizing GS 8 into PC with or without grade 5 should be considered as a stratification factor in randomized trials.
Patient summary : Long-term success rates for men with Gleason score 8 prostate cancer vary depending on whether the most aggressive type of cancer (grade 5) is present at biopsy.
European Urology , résumé, 2014